EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance

Nature Communications

Volumn 7, Issue , 2016, Pages

  Depner, C ^a   Zum Buttel, H ^b   BogUrcu N ^a   Cuesta, A M ^b   Aburto, M R ^b,c   Seidel, S ^a   Finkelmeier, F ^a   Foss, F ^b,c   Hofmann, J ^b   Kaulich, K ^d   Barbus, S ^e   Segarra, M ^b   Reifenberger, G ^d   Garvalov, B K ^a   Acker, T ^a   Acker Palmer, A ^b,c,f  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f MAX PLANCK INSTITUTE FOR BRAIN RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN B2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN; UNCLASSIFIED DRUG; ZEB2 PROTEIN; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; ZEB2 PROTEIN, HUMAN; ZINC FINGER E BOX BINDING HOMEOBOX 2;

BRAIN; GENE EXPRESSION; GENETIC ANALYSIS; HYPOXIA; METHYLATION; PROTEIN; RODENT; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; FEMALE; GENE DELETION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PROMOTER REGION; REPRESSOR GENE; TUMOR INVASION; TUMOR MICROENVIRONMENT; ANIMAL; C57BL MOUSE; CELL HYPOXIA; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; GLIOMA; KNOCKOUT MOUSE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; UPREGULATION; VASCULARIZATION;

MURINAE;

ANGIOGENESIS INHIBITORS; ANIMALS; BEVACIZUMAB; CELL HYPOXIA; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; EPHRIN-B2; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZINC FINGER E-BOX BINDING HOMEOBOX 2;

EID: 84982711413     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12329     Document Type: Article

References (70)

1. Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
2. Kerbel, R. S. Tumor angiogenesis. N. Engl. J. Med. 358, 2039-2049 (2008).
3. Norden, A. D., Drappatz, J. & Wen, P. Y. Antiangiogenic therapies for high-grade glioma. Nat. Rev. Neurol. 5, 610-620 (2009).
4. Bergers, G. & Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592-603 (2008).
5. Chinot, O. L. et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 709-722 (2014).
6. Gilbert, M. R. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 699-708 (2014).
7. Narayana, A. et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J. Neurosurg. 110, 173-180 (2009).
8. Norden, A. D. et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70, 779-787 (2008).
9. DeLay, M. et al. Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. Clin. Cancer Res. 18, 2930-2942 (2012).
10. Ebos, J. M. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232-239 (2009).
11. Keunen, O. et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc. Natl Acad. Sci. USA 108, 3749-3754 (2011).
12. Lu, K. V. et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22, 21-35 (2012).
13. Paez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231 (2009).
14. Sennino, B. & McDonald, D. M. Controlling escape from angiogenesis inhibitors. Nat. Rev. Cancer 12, 699-709 (2012).
15. Sounni, N. E. et al. Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal. Cell Metab. 20, 280-294 (2014).
16. Nieto, M. A. The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu. Rev. Cell Dev. Biol. 27, 347-376 (2011).
17. Semenza, G. L. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu. Rev. Pathol. 9, 47-71 (2014).
18. Pasquale, E. B. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat. Rev. Cancer 10, 165-180 (2010).
19. Egea, J. & Klein, R. Bidirectional Eph-ephrin signaling during axon guidance. Trends. Cell Biol. 17, 230-238 (2007).
20. Klein, R. Eph/ephrin signalling during development. Development 139, 4105-4109 (2012).
21. Batlle, E. et al. EphB receptor activity suppresses colorectal cancer progression. Nature 435, 1126-1130 (2005).
22. Toedt, G. et al. Molecular signatures classify astrocytic gliomas by IDH1 mutation status. Int. J. Cancer 128, 1095-1103 (2011).
23. Grunwald, I. C. et al. Hippocampal plasticity requires postsynaptic ephrinBs. Nat. Neurosci. 7, 33-40 (2004).
24. Blouw, B. et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4, 133-146 (2003).
25. Henze, A. T. et al. Loss of PHD3 allows tumours to overcome hypoxic growth inhibition and sustain proliferation through EGFR. Nat. Commun. 5, 5582 (2014).
26. Sawamiphak, S. et al. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 465, 487-491 (2010).
27. Cortina, C. et al. EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells. Nat. Genet. 39, 1376-1383 (2007).
28. Keith, B., Johnson, R. S. & Simon, M. C. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 12, 9-22 (2011).
29. Yang, J. & Weinberg, R. A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 14, 818-829 (2008).
30. Evans, A. J. et al. VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. Mol. Cell. Biol. 27, 157-169 (2007).
31. Krishnamachary, B. et al. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res. 66, 2725-2731 (2006).
32. Yang, M. H. et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat. Cell Biol. 10, 295-305 (2008).
33. Lester, R. D., Jo, M., Montel, V., Takimoto, S. & Gonias, S. L. uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells. J. Cell Biol. 178, 425-436 (2007).
34. Peinado, H., Olmeda, D. & Cano, A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer 7, 415-428 (2007).
35. De Craene, B. & Berx, G. Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer 13, 97-110 (2013).
36. Kunkel, P. et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. 61, 6624-6628 (2001).
37. Pasquale, E. B. Eph-ephrin bidirectional signaling in physiology and disease. Cell 133, 38-52 (2008).
38. Heroult, M., Schaffner, F. & Augustin, H. G. Eph receptor and ephrin ligandmediated interactions during angiogenesis and tumor progression. Exp. Cell Res. 312, 642-650 (2006).
39. Nakada, M., Drake, K. L., Nakada, S., Niska, J. A. & Berens, M. E. Ephrin-B3 ligand promotes glioma invasion through activation of Rac1. Cancer Res. 66, 8492-8500 (2006).
40. Zagzag, D. et al. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88, 2606-2618 (2000).
41. Erber, R. et al. EphB4 controls blood vascular morphogenesis during postnatal angiogenesis. EMBO J. 25, 628-641 (2006).
42. Tu, Y. et al. Expression of EphrinB2 and EphB4 in glioma tissues correlated to the progression of glioma and the prognosis of glioblastoma patients. Clin. Transl. Oncol. 14, 214-220 (2012).
43. Friedl, P. & Alexander, S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 147, 992-1009 (2011).
44. Joseph, J. V. et al. Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1alpha-ZEB1 axis. Cancer Lett. 359, 107-116 (2015).
45. Liao, H. et al. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2. Oncotarget 6, 8914-8928 (2015).
46. Mahabir, R. et al. Sustained elevation of Snail promotes glial-mesenchymal transition after irradiation in malignant glioma. Neuro. Oncol. 16, 671-685 (2014).
47. Myung, J. K., Choi, S. A., Kim, S. K., Wang, K. C. & Park, S. H. Snail plays an oncogenic role in glioblastoma by promoting epithelial mesenchymal transition. Int. J. Clin. Exp. Pathol. 7, 1977-1987 (2014).
48. Siebzehnrubl, F. A. et al. The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO Mol. Med. 5, 1196-1212 (2013).
49. Yao, C. et al. CXCL12/CXCR4 axis upregulates twist to induce EMT in human glioblastoma. Mol. Neurobiol. 53, 3948-3953 (2016).
50. Zhang, L. et al. SHP-2-upregulated ZEB1 is important for PDGFRalpha-driven glioma epithelial-mesenchymal transition and invasion in mice and humans. Oncogene. doi: 10.1038/onc.2016.100 (2016).
51. Kahlert, U. D. et al. ZEB1 Promotes Invasion in Human Fetal Neural Stem Cells and Hypoxic Glioma Neurospheres. Brain. Pathol. 25, 724-732 (2015).
52. Li, J. et al. MicroRNA-200b inhibits the growth and metastasis of glioma cells via targeting ZEB2. Int. J. Oncol. 48, 541-550 (2016).
53. Pang, H., Zheng, Y., Zhao, Y., Xiu, X. &Wang, J. miR-590-3p suppresses cancer cell migration, invasion and epithelial-mesenchymal transition in glioblastoma multiforme by targeting ZEB1 and ZEB2. Biochem. Biophys. Res. Commun. 468, 739-745 (2015).
54. Pennacchietti, S. et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3, 347-361 (2003).
55. Mittal, K., Ebos, J. & Rini, B. Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond. Semin. Oncol. 41, 235-251 (2014).
56. Mountzios, G., Pentheroudakis, G. & Carmeliet, P. Bevacizumab and micrometastases: revisiting the preclinical and clinical rollercoaster. Pharmacol. Ther. 141, 117-124 (2014).
57. Bensaad, K. et al. Fatty acid uptake and lipid storage induced by HIF-1alpha contribute to cell growth and survival after hypoxia-reoxygenation. Cell Rep. 9, 349-365 (2014).
58. Hattingen, E. et al. Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study. Neuro. Oncol. 13, 1349-1363 (2011).
59. Jahangiri, A. et al. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin. Cancer. Res. 19, 1773-1783 (2013).
60. Kumar, K. et al. Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts. J. Mol. Med. (Berl) 91, 749-758 (2013).
61. Mehta, S. et al. Assessing early therapeutic response to bevacizumab in primary breast cancer using magnetic resonance imaging and gene expression profiles. J. Natl Cancer Inst. Monogr. 2011, 71-74 (2011).
62. Yopp, A. C. et al. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Ann. Surg. Oncol. 18, 2192-2199 (2011).
63. McIntyre, A. & Harris, A. L. Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality. EMBO Mol. Med. 7, 368-379 (2015).
64. Essmann, C. L. et al. Serine phosphorylation of ephrinB2 regulates trafficking of synaptic AMPA receptors. Nat. Neurosci. 11, 1035-1043 (2008).
65. Louis, D. N. et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114, 97-109 (2007).
66. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
67. van den Boom, J. et al. Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am. J. Pathol. 163, 1033-1043 (2003).
68. Grunwald, I. C. et al. Kinase-independent requirement of EphB2 receptors in hippocampal synaptic plasticity. Neuron 32, 1027-1040 (2001).
69. Palmer, A. et al. EphrinB phosphorylation and reverse signaling: regulation by Src kinases and PTP-BL phosphatase. Mol. Cell 9, 725-737 (2002).
70. Shaw, L. M. Tumor cell invasion assays. Methods Mol. Biol. 294, 97-105 (2005).